Full-Time
Posted on 6/27/2024
Develops RNA-based medicines and therapies
Expert
Cambridge, MA, USA
Orbital Therapeutics focuses on developing RNA-based medicines, specifically targeting areas like vaccines, immunomodulation, and protein replacement. The company utilizes RNA technology along with advanced delivery methods and data science to create a platform for a wide range of therapeutic applications. Unlike many competitors, Orbital Therapeutics does not work with small interfering RNA, allowing it to carve out a unique niche in the genetic medicine space. The goal is to enhance global health by harnessing RNA medicines to treat diseases in innovative ways that were not possible before. Revenue is generated through the sale of these RNA-based therapies to healthcare providers, who then administer them to patients.
Company Size
51-200
Company Stage
Series A
Total Funding
$262.6M
Headquarters
San Francisco, California
Founded
2022
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Orbital Therapeutics appoints Anna Dixon as senior vice president, human resources.
Orbital Therapeutics appoints veteran biopharma leader, Ron Philip, as chief executive officer.
Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today ann
Orbital is developing an RNA platform that can combine well-known and upcoming RNA technologies and delivery systems.
Orbital Therapeutics aims to develop RNA-based therapeutics for various human diseases, including next-generation vaccines, immunomodulation, and protein replacement.